Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Triple Negative Breast Neoplasms 8Breast Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasms 5Neoplasm Metastasis 4Lung Neoplasms 4Adenocarcinoma 3Stomach Neoplasms 2Pancreatic Diseases 2Neoplasms by Site 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Digestive System Neoplasms 2Digestive System Diseases 2Carcinoma, Pancreatic Ductal 2Carcinoma, Ductal, Breast 2Carcinoma 2Uterine Cervical Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1Radiation Injuries 1Pericardial Effusion 1Pancreatic Cancer Non-resectable 1Pancreatic Adenocarcinoma 1Non-Small-Cell Lung 1Non Small Cell Lung Cancer NSCLC 1Neuralgia 1Neoplasms, Unknown Primary 1

Interventions

spartalizumab 1sintilimab 1pyrotinib 1pertuzumab 1palbociclib 1Trastuzumab 1Taxes 1Letrozole 1Everolimus 1Capecitabine 1Albumin-Bound Paclitaxel 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × HER2+ Breast Cancer × Albumin-Bound Paclitaxel × Clear all
NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

First Affiliated Hospital Xi'an Jiaotong University

Phase 3 Unknown
120 enrolled
Breast

HER2+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡